New MRI lung scanning method could change treatment for compromised lung function in transplant patients. Read on!

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.

Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to ...

A meta-analysis found that peer reviews in radiation oncology led to recommendations to change treatment plans in more than ...

Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...

Johnson & Johnson said its combination therapy for lung cancer outperformed AstraZeneca Plc’s blockbuster Tagrisso in a ...

Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Although lung cancer survival is improving in the United States, 21% of patients with lung cancer did not receive treatment ...

A TRANSPLANT recipient has died of cancer after contracting the illness from his organ donor. The unnamed patient, 69, from Arizona underwent an organ transplant to treat his liver ...

Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...